Phreesia AI Stock Analysis
Phreesia (0A23) AI Stock Analysis
Phreesia
(LSE:0A23)
No summary available
Phreesia (0A23) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $795.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 199
- Price to Earnings (P/E)
- 73.8
- Beta (1Y)
- 0.10
- Revenue Growth
- 12.93%
- EPS Growth
- ―
- Country
- UK
- Employees
- 1,789
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Phreesia Business Overview & Revenue Model
Company Description
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake proc...
Phreesia Earnings Call Summary
The call was strongly constructive, with 10% year-over-year revenue growth, substantial adjusted EBITDA expansion, positive net income for the fifth consecutive quarter, continued positive cash flow, more than $23 million of debt reduction, and reaffirmed fiscal 2027 guidance. AccessOne, Provider Connect, the GLP-1 campaign, and AI initiatives showed encouraging momentum. The main challenges were sequential declines tied to payment-processing seasonality, provider economic strain, pricing moderation, and some earlier volume weakness beyond seasonality.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 2027, Phreesia is maintaining its revenue outlook at a range of $510 million to $520 million, including approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027; adjusted EBITDA guidance remains at a range of $125 million to $135 million, with the restructuring plan expected to result in meaningful annualized run rate expense savings, and AHSC growth expected in the mid-single-digit percentage range and total revenue per AHSC growth in the low single-digit percentage range.
Phreesia Risk Analysis
Phreesia disclosed 57 risk factors in its most recent earnings report. Phreesia reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPhreesia Peers Comparison
Overall Rating
WAY76Outperform
CCLD66Neutral
EVH58Neutral
AMWL57Neutral
HCAT51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $5.41B | 39.86 | 3.41% | ― | 21.43% | 9.80% | |
| 66Neutral | $94.88M | 17.27 | 24.48% | ― | 14.86% | 214.99% | |
| 58Neutral | $546.30M | -1.07 | -129.54% | ― | 14.06% | -189.46% | |
| 57Neutral | $195.28M | -3.30 | -25.49% | ― | -20.30% | 52.30% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $105.09M | -0.49 | -128.24% | ― | -13.88% | -78.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A23 | Phreesia | 10.00 | -18.50 | -64.91% | |
| CCLD | Carecloud, Inc. | 2.23 | -0.75 | -25.17% | |
| EVH | Evolent Health Inc. | 4.83 | 0.83 | 20.75% | |
| HCAT | Health Catalyst | 1.38 | -0.79 | -36.41% | |
| AMWL | American Well Corporation | 11.34 | 7.32 | 182.09% | |
| WAY | Waystar Holding Corp. | 28.11 | -6.76 | -19.39% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
